Does the media prefer CTMX or NRIX?

In the previous week, CytomX Therapeutics and CytomX Therapeutics both had 4 articles in the media. Nurix Therapeutics' average media sentiment score of 0.97 beat CytomX Therapeutics' score of -0.48 indicating that Nurix Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Nurix Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BEAM or CTMX?

In the previous week, Beam Therapeutics had 1 more articles in the media than CytomX Therapeutics. MarketBeat recorded 5 mentions for Beam Therapeutics and 4 mentions for CytomX Therapeutics. Beam Therapeutics' average media sentiment score of 1.17 beat CytomX Therapeutics' score of -0.48 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CTMX or RARE?

In the previous week, Ultragenyx Pharmaceutical had 28 more articles in the media than CytomX Therapeutics. MarketBeat recorded 32 mentions for Ultragenyx Pharmaceutical and 4 mentions for CytomX Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 1.04 beat CytomX Therapeutics' score of -0.48 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ultragenyx Pharmaceutical 20 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SLS or CTMX?

In the previous week, SELLAS Life Sciences Group had 4 more articles in the media than CytomX Therapeutics. MarketBeat recorded 8 mentions for SELLAS Life Sciences Group and 4 mentions for CytomX Therapeutics. SELLAS Life Sciences Group's average media sentiment score of 0.46 beat CytomX Therapeutics' score of -0.48 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral CytomX Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor COAG or CTMX?

In the previous week, CytomX Therapeutics had 2 more articles in the media than Hemab Therapeutics. MarketBeat recorded 4 mentions for CytomX Therapeutics and 2 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 0.00 beat CytomX Therapeutics' score of -0.48 indicating that Hemab Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CytomX Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

CytomX Therapeutics (CTMX) Competitors

$3.28 -0.01 (-0.30%)

As of 08/21/2026 04:00 PM Eastern

Compare

CTMX vs. NRIX, BEAM, RARE, SLS, and COAG

Should you buy CytomX Therapeutics stock or one of its competitors? CytomX Therapeutics's main competitors and comparable companies include Nurix Therapeutics (NRIX), Beam Therapeutics (BEAM), Ultragenyx Pharmaceutical (RARE), SELLAS Life Sciences Group (SLS), and Hemab Therapeutics (COAG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CytomX Therapeutics compare to Nurix Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Nurix Therapeutics (NASDAQ:NRIX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

CytomX Therapeutics has a net margin of -435.21% compared to Nurix Therapeutics' net margin of -928.44%. CytomX Therapeutics' return on equity of -38.46% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-435.21%	-38.46%	-30.33%
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

CytomX Therapeutics has a beta of 2.12, indicating that its share price is 112% more volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market.

CytomX Therapeutics has higher earnings, but lower revenue than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	9.38	-$17.37M	-$0.50	N/A
Nurix Therapeutics	$83.98M	33.02	-$264.46M	-$3.45	N/A

67.8% of CytomX Therapeutics shares are held by institutional investors. 3.8% of CytomX Therapeutics shares are held by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CytomX Therapeutics presently has a consensus target price of $11.90, suggesting a potential upside of 262.80%. Nurix Therapeutics has a consensus target price of $34.21, suggesting a potential upside of 28.05%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe CytomX Therapeutics is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, CytomX Therapeutics and CytomX Therapeutics both had 4 articles in the media. Nurix Therapeutics' average media sentiment score of 0.97 beat CytomX Therapeutics' score of -0.48 indicating that Nurix Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nurix Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CytomX Therapeutics beats Nurix Therapeutics on 11 of the 16 factors compared between the two stocks.

How does CytomX Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and CytomX Therapeutics (NASDAQ:CTMX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Beam Therapeutics presently has a consensus target price of $49.00, suggesting a potential upside of 64.65%. CytomX Therapeutics has a consensus target price of $11.90, suggesting a potential upside of 262.80%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CytomX Therapeutics is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by insiders. Comparatively, 3.8% of CytomX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Beam Therapeutics had 1 more articles in the media than CytomX Therapeutics. MarketBeat recorded 5 mentions for Beam Therapeutics and 4 mentions for CytomX Therapeutics. Beam Therapeutics' average media sentiment score of 1.17 beat CytomX Therapeutics' score of -0.48 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Beam Therapeutics has a net margin of -54.75% compared to CytomX Therapeutics' net margin of -435.21%. Beam Therapeutics' return on equity of -30.71% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

CytomX Therapeutics has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	22.00	-$79.99M	-$0.86	N/A
CytomX Therapeutics	$76.20M	9.38	-$17.37M	-$0.50	N/A

Beam Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.12, suggesting that its share price is 112% more volatile than the broader market.

Summary

Beam Therapeutics beats CytomX Therapeutics on 10 of the 16 factors compared between the two stocks.

How does CytomX Therapeutics compare to Ultragenyx Pharmaceutical?

CytomX Therapeutics (NASDAQ:CTMX) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

In the previous week, Ultragenyx Pharmaceutical had 28 more articles in the media than CytomX Therapeutics. MarketBeat recorded 32 mentions for Ultragenyx Pharmaceutical and 4 mentions for CytomX Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 1.04 beat CytomX Therapeutics' score of -0.48 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	20 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Ultragenyx Pharmaceutical has a net margin of -81.79% compared to CytomX Therapeutics' net margin of -435.21%. CytomX Therapeutics' return on equity of -38.46% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-435.21%	-38.46%	-30.33%
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%

CytomX Therapeutics presently has a consensus price target of $11.90, suggesting a potential upside of 262.80%. Ultragenyx Pharmaceutical has a consensus price target of $58.89, suggesting a potential upside of 127.99%. Given CytomX Therapeutics' higher possible upside, equities research analysts clearly believe CytomX Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.84

CytomX Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	9.38	-$17.37M	-$0.50	N/A
Ultragenyx Pharmaceutical	$673M	3.78	-$575M	-$5.84	N/A

CytomX Therapeutics has a beta of 2.12, indicating that its share price is 112% more volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Summary

Ultragenyx Pharmaceutical beats CytomX Therapeutics on 9 of the 16 factors compared between the two stocks.

How does CytomX Therapeutics compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and CytomX Therapeutics (NASDAQ:CTMX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

CytomX Therapeutics has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A
CytomX Therapeutics	$76.20M	9.38	-$17.37M	-$0.50	N/A

SELLAS Life Sciences Group has a beta of 2.48, indicating that its share price is 148% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.12, indicating that its share price is 112% more volatile than the broader market.

In the previous week, SELLAS Life Sciences Group had 4 more articles in the media than CytomX Therapeutics. MarketBeat recorded 8 mentions for SELLAS Life Sciences Group and 4 mentions for CytomX Therapeutics. SELLAS Life Sciences Group's average media sentiment score of 0.46 beat CytomX Therapeutics' score of -0.48 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
CytomX Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

SELLAS Life Sciences Group currently has a consensus target price of $10.00, indicating a potential downside of 35.32%. CytomX Therapeutics has a consensus target price of $11.90, indicating a potential upside of 262.80%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

SELLAS Life Sciences Group has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -435.21%. SELLAS Life Sciences Group's return on equity of -35.91% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

Summary

CytomX Therapeutics beats SELLAS Life Sciences Group on 10 of the 16 factors compared between the two stocks.

How does CytomX Therapeutics compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and CytomX Therapeutics (NASDAQ:CTMX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

Hemab Therapeutics has higher earnings, but lower revenue than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A
CytomX Therapeutics	$76.20M	9.38	-$17.37M	-$0.50	N/A

In the previous week, CytomX Therapeutics had 2 more articles in the media than Hemab Therapeutics. MarketBeat recorded 4 mentions for CytomX Therapeutics and 2 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 0.00 beat CytomX Therapeutics' score of -0.48 indicating that Hemab Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CytomX Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

67.8% of CytomX Therapeutics shares are held by institutional investors. 3.8% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Hemab Therapeutics currently has a consensus price target of $51.40, indicating a potential upside of 4.56%. CytomX Therapeutics has a consensus price target of $11.90, indicating a potential upside of 262.80%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Hemab Therapeutics has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -435.21%. Hemab Therapeutics' return on equity of 0.00% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

Summary

CytomX Therapeutics beats Hemab Therapeutics on 9 of the 14 factors compared between the two stocks.

Get CytomX Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTMX vs. The Competition

Export

Metric	CytomX Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$714.71M	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-6.56	11.62	272.60	24.24
Price / Sales	9.38	1,338.17	618.96	99.78
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	2.36	16.80	13.05	6.20
Net Income	-$17.37M	-$12.50M	$3.47B	$348.59M
7 Day Performance	-2.38%	3.29%	2.09%	0.08%
1 Month Performance	-1.50%	8.23%	6.64%	3.88%
1 Year Performance	54.72%	55.05%	25.02%	16.98%

CytomX Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTMX CytomX Therapeutics	2.4983 of 5 stars	$3.28 -0.3%	$11.90 +262.8%	+54.7%	$714.71M	$76.20M	N/A	170	Analyst Downgrade
NRIX Nurix Therapeutics	2.9169 of 5 stars	$27.17 +0.4%	$34.21 +25.9%	+163.5%	$2.81B	$36.77M	N/A	300	Positive News
BEAM Beam Therapeutics	2.1691 of 5 stars	$27.10 +1.3%	$49.00 +80.8%	+78.8%	$2.76B	$156.04M	N/A	510	Positive News
RARE Ultragenyx Pharmaceutical	3.442 of 5 stars	$26.13 -1.4%	$57.82 +121.3%	-13.3%	$2.61B	$673M	N/A	1,371	Trending News Analyst Forecast
SLS SELLAS Life Sciences Group	0.7974 of 5 stars	$13.00 +1.7%	$10.00 -23.1%	+709.4%	$2.58B	N/A	N/A	10	News Coverage Options Volume Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTMX) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CytomX Therapeutics (CTMX) Competitors

CTMX vs. NRIX, BEAM, RARE, SLS, and COAG

How does CytomX Therapeutics compare to Nurix Therapeutics?

Summary

How does CytomX Therapeutics compare to Beam Therapeutics?

Summary

How does CytomX Therapeutics compare to Ultragenyx Pharmaceutical?

Summary

How does CytomX Therapeutics compare to SELLAS Life Sciences Group?

Summary

How does CytomX Therapeutics compare to Hemab Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX vs. The Competition

CytomX Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CytomX Therapeutics (CTMX) Competitors

CTMX vs. NRIX, BEAM, RARE, SLS, and COAG

How does CytomX Therapeutics compare to Nurix Therapeutics?

Is CTMX or NRIX more profitable?

Which has more volatility and risk, CTMX or NRIX?

Which has stronger valuation & earnings, CTMX or NRIX?

Do insiders and institutionals hold more shares of CTMX or NRIX?

Do analysts rate CTMX or NRIX?

Does the media prefer CTMX or NRIX?

Summary

How does CytomX Therapeutics compare to Beam Therapeutics?

Do analysts recommend BEAM or CTMX?

Do insiders & institutionals have more ownership in BEAM or CTMX?

Does the media refer more to BEAM or CTMX?

Is BEAM or CTMX more profitable?

Which has preferable valuation & earnings, BEAM or CTMX?

Which has more volatility & risk, BEAM or CTMX?

Summary

How does CytomX Therapeutics compare to Ultragenyx Pharmaceutical?

Does the media prefer CTMX or RARE?

Do insiders & institutionals hold more shares of CTMX or RARE?

Is CTMX or RARE more profitable?

Do analysts prefer CTMX or RARE?

Which has preferable valuation & earnings, CTMX or RARE?

Which has more risk & volatility, CTMX or RARE?

Summary

How does CytomX Therapeutics compare to SELLAS Life Sciences Group?

Which has higher valuation and earnings, SLS or CTMX?

Which has more risk & volatility, SLS or CTMX?

Does the media favor SLS or CTMX?

Do insiders and institutionals have more ownership in SLS or CTMX?

Do analysts rate SLS or CTMX?

Is SLS or CTMX more profitable?

Summary

How does CytomX Therapeutics compare to Hemab Therapeutics?

Which has preferable valuation & earnings, COAG or CTMX?

Does the media favor COAG or CTMX?

Do insiders & institutionals have more ownership in COAG or CTMX?

Do analysts recommend COAG or CTMX?

Is COAG or CTMX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX vs. The Competition

CytomX Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools